In summary, PET molecular imaging using 18F-FES, which assesses ERα expression, and quantitative measurement of the 18F-FDG/18F-FES SUV ratio may be useful for predicting outcomes in uterine sarcoma patients. This evidence concerns the gene ESR1 and uterine corpus sarcoma.